The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020.
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020.
复制标题
DOI：
10.1186/s12967-021-02811-8
复制
发表时间：
2021-04-07
影响因子：
7.4
通讯作者：
Puzanov I
中科院分区：
文献类型：
--
作者：
Ascierto PA;Brody J;Butterfield LH;Finn OJ;Goldberg J;Perrone F;Sullivan RJ;Fox BA;Hwu P;Puzanov I
作为2020年免疫治疗桥虚拟大会（12月2日至3日，意大利）的一部分，大辩论会议精选了当今免疫治疗三个临床问题的领先专家的观点。第一个问题是抗肿瘤疫苗接种是否仍然是一种治疗选择。第二个主题讨论了抗程序性死亡（PD）-1/PD-配体（L）1阻断是否应该成为免疫治疗组合的支柱。最后，从学术和行业角度考虑了创新研究设计和替代终点的使用。对于每个专题，两名专家提出了支持两种不同观点的论点和反论点。与以往的桥梁大会一样，辩论是由会议主席指定的，专家在辩论中采取的立场可能不一定反映他们各自的个人观点。本文中总结的观点基于现有证据，但可能反映了对这些数据的个人解释，临床经验和发言者的主观意见。
As part of the 2020 Immunotherapy Bridge virtual congress (December 2nd–3rd, Italy), the Great Debate session featured counterpoint views from leading experts on three clinical questions in immunotherapy today. The first of these was whether antitumoral vaccination is still a treatment option. The second topic debated whether anti-programmed death (PD)-1/PD-ligand (L)1 blockade should be the backbone for immunotherapy combination. Finally, the use of innovative study designs and surrogate endpoints was considered from both an academic and industry perspective. For each topic, two experts presented the argument and counter-argument in support of two different points of view. As with previous Bridge congresses, the debates were assigned by meeting Chairs and positions taken by experts during the debates may not have necessarily reflected their respective personal view. The views summarised in this article are based on available evidence but may reflect personal interpretation of these data, clinical experience and subjective opinion of the speaker.
登录
查看更多内容
DOI：
10.1056/nejmoa1707447
发表时间：
2017-12-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Neelapu SS;Locke FL;Bartlett NL;Lekakis LJ;Miklos DB;Jacobson CA;Braunschweig I;Oluwole OO;Siddiqi T;Lin Y;Timmerman JM;Stiff PJ;Friedberg JW;Flinn IW;Goy A;Hill BT;Smith MR;Deol A;Farooq U;McSweeney P;Munoz J;Avivi I;Castro JE;Westin JR;Chavez JC;Ghobadi A;Komanduri KV;Levy R;Jacobsen ED;Witzig TE;Reagan P;Bot A;Rossi J;Navale L;Jiang Y;Aycock J;Elias M;Chang D;Wiezorek J;Go WY
通讯作者：
Go WY
影响因子：
10.9
作者：
Butterfield, Lisa H.;Vujanovic, Lazar;Kirkwood, John M.
通讯作者：
Kirkwood, John M.
影响因子：
10.1
作者：
Maurer DM;Adamik J;Santos PM;Shi J;Shurin MR;Kirkwood JM;Storkus WJ;Butterfield LH
通讯作者：
Butterfield LH
影响因子：
4
作者：
Berzofsky JA;Terabe M;Wood LV
通讯作者：
Wood LV
DOI：
10.1136/bmj.j4530
发表时间：
2017-10-04
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Davis C;Naci H;Gurpinar E;Poplavska E;Pinto A;Aggarwal A
通讯作者：
Aggarwal A